CAT #: 13110011
PML/RARα Translocation Assay for ABI Fluorescence Detection
This Research Use Only assay identifies PML/RARα t(15;17) translocations.
Summary and Explanation of the Test
Three PML/RARα translocation patterns have been identified in samples with acute myelogenous leukemia (AML): type A is the short (S-form); the breakpoint occurs within breakpoint cluster region 3 (Bcr-3). Type B is the long (L-form); the breakpoint occurs within Bcr-1. There is a third type B variant or variable (V-form); the breakpoint is within Bcr-2. Identification of the PML/RARα t(15;17) rearrangements are commonly used in the study of APL because it is correlated with responsiveness to treatment. This RT-PCR method directly identifies the chimeric PML/RARα transcripts expressed from all three forms of PML/RARα translocations.
This assay tests complementary DNA (cDNA) template. Please refer to the IFU for protocols on extracting RNA and making cDNA.
Warranty and Liability
Invivoscribe, Inc. (Invivoscribe®) is committed to providing the highest quality products. Invivoscribe® warrants that the products meet or exceed the performance standards described in the Instructions For Use, as to products with such an insert. If a product is covered by product specifications and does not perform as specified, our policy is to replace the product or credit the full purchase price. No other warranties of any kind, expressed or implied, are provided by Invivoscribe®. Invivoscribe® liability shall not exceed the purchase price of the product. Invivoscribe® shall have no liability for direct, indirect, consequential or incidental damages arising from the use, results of use, or inability to use its products; product efficacy under purchaser controlled conditions in purchaser’s laboratory must be established and continually monitored through purchaser defined and controlled processes including but not limited to testing of positive, negative, and blank controls every time a sample is tested. Ordering, acceptance, and use of product constitutes purchaser acceptance of sole responsibility for assuring product efficacy and purchaser agreement to the limitation of liability set forth in this paragraph.
This product is for Research Use Only; not for use in diagnostic procedures.
This product is covered by one or more of the following: European Patent Number 1549764, European Patent Number 2418287, European Patent Number 2460889, Japanese Patent Number 4708029, United States Patent 8859748, United States Patent 10280462, and related pending and future applications. All of these patents and applications are licensed exclusively to Invivoscribe®. Additional patents licensed to Invivoscribe® covering some of these products apply elsewhere. Many of these products require nucleic acid amplification methods such as Polymerase Chain Reaction (PCR). No license under these patents to use amplification processes or enzymes is conveyed expressly or by implication to the purchaser by the purchase of this product.
©2020 Invivoscribe, Inc. All rights reserved. The trademarks mentioned herein are the property of Invivoscribe, Inc. and/or its affiliates, or (as to the trademarks of others used herein) their respective owners.